When will Blinatumomab be included in medical insurance?

Blinatumomab is a biologic agent used to treat acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia, ALL), especially relapsed or refractory B cell acute lymphoblastic leukemia. This drug has attracted widespread attention and interest in the field of leukemia treatment.

Belintuzumab has been launched in China, but it has not yet been included in medical insurance. The domestic price is about 10,000 yuan. Please consult the local hospital pharmacy for specific prices.

Belintuzumab’s mechanism of action is unique and compelling. It is a type of chimeric T cell receptor (CAR-T) therapy that enhances the patient's immune system's ability to attack leukemia cells by connecting T cells and B cells. Specifically, belintuzumab is a bispecific antibody that binds to CD3-positive T cells on one end and CD19-positive B cells on the other end. This structure allows T cells to recognize and attack B cells, thereby destroying leukemia cells and improving the accuracy of treatment.

In terms of clinical application, belintuzumab has achieved remarkable results in many research and clinical trials. It is often used in patients with ALLwho are resistant to traditional treatments, for whom traditional treatments often have limited efficacy. The therapeutic effect of belintuzumab is encouraging and can achieve a remission rate of up to 80%. At the same time, the side effects are relatively mild, mainly manifesting as some symptoms related to T cell activation, such as fever and headache.

In the future, belintuzumab may continue to play an important role in the treatment of leukemia, while also providing new ideas for research on other types of cancer therapies. Not only that, with further research and clinical application, we can expect to see its application in a wider range of cancer types and patient groups, making a greater contribution to improving patients' survival rates and quality of life.